ABSOLUTE PASI REDUCTIONS IN A PHASE 2B TRIAL OF THE SELECTIVE ORAL TYK2 INHIBITOR, TAK-279, IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Green, Lawrence [1 ]
Ferris, Laura [2 ]
Moore, Angela [3 ,7 ,8 ]
Zirwas, Matthew [4 ]
Zhao, Yiwei [5 ]
Blau, Jessamyn [5 ]
Zhang, Wenwen [5 ]
Uy, Jonathan [5 ]
Winkelman, Warren [5 ]
Vender, Ronald [6 ]
机构：
[1] George Washington Univ, Sch Med, Rockville, MD USA
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] Dermatologists Greater Columbus, Columbus, OH USA
[5] Takeda Dev Ctr Amer Inc, Cambridge, MA USA
[6] Dermatrials Res Inc, Hamilton, ON, Canada
[7] Arlington Res Ctr, Arlington, TX USA
[8] Arlington Ctr Dermatol, Arlington, TX USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P-069
引用
收藏
页数：102
相关论文
共 50 条
  • [31] Apremilast in moderate-to-severe plaque psoriasis (ESTEEM 2 trial)
    Anstey, Alex
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) : E23 - E23
  • [32] Selective oral tyrosine kinase 2 (TYK2) inhibitor (BMS-986165) impact on quality of life (QOL) in patients with moderate to severe plaque psoriasis (PSO) in a phase 2 trial as assessed by the dermatology life quality index (DLQI)
    Thaci, D.
    Papp, K.
    Gordon, K.
    Morita, A.
    Gooderham, M.
    Foley, P.
    Kisa, R.
    Napoli, A.
    Kundu, S.
    Banerjee, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 71 - 72
  • [33] Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis
    Zheng, Yaxuan
    Han, Yue
    Chen, Jincong
    Huang, Jiahao
    Zhu, Changhua
    Lin, Lihang
    Su, Huichun
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2024, 90 (05): : 590 - 598
  • [34] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate/severe plaque psoriasis: onset of action in the phase 3 POETYK PSO-1 and PSO-2 trials
    Foley, Peter
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 65 - 65
  • [35] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
    Armstrong, A.
    Gooderham, M.
    Warren, R. B.
    Papp, K.
    Strober, B.
    Thaci, D.
    Colston, E.
    Throup, J.
    Kundu, S.
    Banerjee, S.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 795 - 796
  • [36] Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial
    Imafuku, Shinichi
    Tada, Yayoi
    Hippeli, Lauren
    Banerjee, Subhashis
    Morita, Akimichi
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2023, 50 (05): : 588 - 595
  • [37] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials
    Spelman, Lynda
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 66 - 66
  • [38] IMPACT OF ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 TRIAL
    Gottlieb, A. B.
    Armstrong, A.
    Merola, J. F.
    Napoli, A.
    Nowak, M.
    Banerjee, S.
    Lehman, T.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1145 - 1146
  • [39] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials
    Armstrong, April W.
    Warren, Richard B.
    Sofen, Howard
    Spelman, Lynda
    Leonardi, Craig
    Banerjee, Subhashis
    Wang, Tao
    Throup, John
    Colston, Elizabeth
    Napoli, Andrew
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB156 - AB156
  • [40] Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis
    Poulin, Y.
    Ramon, M.
    Rosoph, L.
    Weisman, J.
    Mendelsohn, A. M.
    Parno, J.
    Rozzo, S. J.
    Lee, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (07) : 1500 - 1509
12345